Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Healthcare Cost Drivers topic

No spam. Unsubscribe anytime.

Consultants: specialty prescriptions and non‑preferred enrollment boosting costs; clinic engagement and case management highlighted

2390211 · February 25, 2025
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Benefits consultants told the committee prescription drugs now dominate claim increases and urged greater use of county clinics and case management; a vendor presentation on a weight‑loss program (1-to-1) was deferred to old business for further review.

Consultants reviewing Sumner County’s self‑insured plans told the Self Insurance Board Committee that prescription drug spending — and particularly specialty medications — has become the largest driver of rising claims, and that a relatively small non‑preferred enrollee population showed steep year‑to‑year increases.

The consultant noted a Rx rebate hit in January that temporarily improved month‑to‑month cash flow, but cautioned the board that per‑employee‑per‑month (PEPM) prescription costs are trending up. Consultants and county staff credited the county’s onsite clinics and wellness programs for lowering overall costs for engaged members, and said the county could reduce expenses further by driving more visits and prescriptions through the clinic network and through mail‑order programs (AS Meds was cited as an existing mail‑order vendor).

The committee also heard a vendor presentation about a medically supervised weight‑loss program that includes lifestyle preconditions and, if criteria are met, access to GLP‑1 class medications such as Wegovy. The consultant warned GLP‑1 therapy can cost hundreds to more than $1,400 per month at retail; the vendor said its reduced procurement through AS Meds would still cost the plan roughly $808–$1,465 per month for GLP‑1 therapy depending on product and supply route. The board directed staff to return with modeled savings estimates; members agreed to move the vendor presentation into “old business” for further analysis rather than take immediate action.

Consultants recommended broader outreach — including targeted text campaigns and mailers — to engage dependents who under‑utilize clinics, and outlined a case‑management option that would place an RN to coordinate care for high‑cost claimants. The RN’s salary split proposal estimated the county’s portion at roughly $28,000 per year if the school system continued to absorb the larger share.